Patients who discontinued statin treatment: A protocol for cohort study using primary care data

BMJ Open

Volumn 5, Issue 10, 2015, Pages

  Vinogradova, Yana ^a   Coupland, Carol ^a   Brindle, Peter ^b   Hippisley Cox, Julia ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Bristol Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; NON PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG WITHDRAWAL; FEMALE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOL; FACTUAL DATABASE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; STANDARDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 84945911272     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008701     Document Type: Article

References (45)

1. British Heart Foundation. Cardiovascular Disease Statistics UK Factsheet. 2015. https://www.bhf.org.uk/research/heart-statistics (accessed 19 Oct. 2015).
2. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
3. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Clinical guideline 67. London: NICE, 2008.
4. Mihaylova, B Emberson, J Blackwell, L, et al. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
5. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Clinical guideline 181. London: NICE, 2014.
6. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25, Part B):2889-934.
7. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: a lost opportunity. Pharmacotherapy 2001;21:576-82.
8. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35.
9. Jasinska-Stroschein M, Owczarek J, Wejman I, et al. Novel mechanistic and clinical implications concerning the safety of statin discontinuation. Pharmacol Rep 2011;63:867-79.
10. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
11. Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-7.
12. Risselada R, Straatman H, Van Kooten F, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 2009;40:2887-92.
13. McGowan MP, Treating to New Target (TNT) Study Group. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-5.
14. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014;349:g3743.
15. Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109-17.
16. Macedo A, Douglas I, Smeeth L, et al. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice research datalink. BMC Cardiovasc Disord 2014;14:85.
17. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-82.
18. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
19. Ray KK, Seshasai S, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: A meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010;170:1024-31.
20. Abramson JD, Rosenberg HG, Jewell N, et al. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123.
21. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7.
22. Taylor F, Huffman M, Macedo A, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1: CD004816.
23. Malhotra A. Saturated fat is not the major issue. BMJ 2013;347:f6340.
24. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland, 2003.
25. Bardel A, Wallander M-A, Svärdsudd K. Factors associated with adherence to drug therapy: a population-based study. Eur J Clin Pharmacol 2007;63:307-14.
26. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9.
27. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158:526-34.
28. Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 2012;28:574-80.
29. Daskalopoulou SS, Delaney JAC, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008;29:2083-91.
30. Yang C-C, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol 2003;56:84-91.
31. Fahey T, Smith S. Re: adverse effects of statins. BMJ 2014;348:g3306.
32. Hippisley-Cox J, Parker C, Coupland C, et al. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart 2007;93:1256-62.
33. Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001;322:832.
34. O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. BMJ Open 2015;5:e007207.
35. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
36. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
37. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM 2003;96:337-43.
38. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36.
39. Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary 66. London: Pharmaceutical Press, 2013.
40. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74.
41. Royston P. Multiple imputation of missing values. Stata J 2004;4:227-41.
42. Steyerberg EW, Van Veen M. Imputation is beneficial for handling missing data in predictive models. J Clin Epidemiol 2007;60:979.
43. Lemstra M, Blackburn D. Nonadherence to statin therapy: discontinuation after a single fill. Can J Cardiol 2012;28:567-73.
44. Mainous Iii AG, Baker R, Everett CJ, et al. Impact of a policy allowing for over-the-counter statins. Qual Prim Care 2010;18:301-6.
45. McGinnis B, Olson K, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007;41:1805-11.